ArcticZymes Technologies ASA – Invitation to Capital Markets Day 2026 - 6 March 2026, 09:00–12:00 CET - Stockholm, Sweden
ArcticZymes Technologies ASA invites investors, analysts and other stakeholders to its Capital Markets Day on 6 March 2026, 09:00–12:00 CET (registration and coffee from 08:30).
ArcticZymes Technologies ASA Capital Markets Day 2026 [Video]
Watch ArcticZymes’ management team outline the strategy to scale and diversify its enzyme platform across biomanufacturing and molecular tools.
ArcticZymes Releases New White Paper Quantifying the Impact of Optimized Nuclease Strategy on Viral Vector Manufacturing Economics
Explore how different nucleases can significantly impact viral vector manufacturing yield, downstream process complexity and product purity in this new white paper. This innovative model is based upon published data, provides researcher and bioprocess engineers with a new insight into how small changes can have significant impacts resulting in lower costs per dose.
ArcticZymes Technologies Reports Strong Q4 and FY 2025 Results: Accelerating Sales Growth and Improved Profitability
Tromsø, Norway, February 12, 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported financial results for the fourth quarter and full year 2025, reflecting accelerating sales growth, improved operating leverage and continued penetration in its core business segments. Following a return to growth in 2025, the Company enters 2026 with strengthened commercial momentum and a robust balance sheet.
ArcticZymes Technologies Reports Q3 2025 Results: Continued Growth Momentum and Strengthened Profitability
Tromsø, Norway, November 6, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the third quarter of 2025, reporting strong topline growth and solid operational performance.